Hungary starts vaccinating with Sputnik V | It’s him …

The Sputnik V vaccine reaches Hungary, making it the first country in the European Union (EU) to integrate the Centro Gamaleya vaccine. The country had already considered its approval since the end of January due to delays by the European Medicines Agency (EMA) to start vaccination with the drug AstraZeneca.

From the Russian Direct Investment Fund (RDIF), they announced that three other countries (Montenegro, Saint Vincent and the Grenadines and Kazakhstan) have been registered for the use of this vaccine. A total of 27 countries have already approved its use. Although several European governments have made public their interest in Sputnik V, it has not yet been authorized by the European regulator.

In Hungary, the Director General of Health, Cecilia Muller, reported on the progress of the vaccination process at a press conference. “Today we are starting to vaccinate with the Sputnik V vaccine, this will happen in the designated vaccination centers”. The drug from the Gamaleya Center began to be used this Friday in the capital Budapest, in principle with around 2,800 doses. Muller also spoke about the importance of containing the spread of new variants of covid-19, including the UK variant.

Prime Minister Viktor Orban spoke at a press conference on the progress of the vaccination process in the European country, where the pace of this campaign allowed more than 380,000 people have been vaccinated with one of the three medicines approved by the EU (Pfizer / BioNTech, Moderna and AstraZeneca).

Too assured that with the incorporation of the Sputnik V and Sinopharm vaccines, the country will be able to inoculate 20 percent of the population -more than two million people- against covid-19 for the arrival of Easter. Next week Hungary also expects to receive the first 500,000 doses of Sinopharm.

The Lancet, a prestigious scientific journal from the United Kingdom published in early February the provisional results of the third phase of the clinical trial of the Sputnik V vaccine. confirmed the safety and efficacy of 91.6% of the Gamaleya Institute vaccine. The tests also revealed that vaccine offers complete protection against severe cases of coronavirus. On February 7, five days after the publication of The Lancet, Hungary approved the use of Sputnik V.

On the other hand, Orban also defended the ability of experts from his country to evaluate different vaccines. “We must trust each other”, stressed the Hungarian Prime Minister. “Every day that we spend waiting, the country loses another person, so we won’t wait.”. The European country has more than 380,000 cases of coronavirus and 13,543 deaths. It was only the last day that recorded over 1,800 new cases and 97 deaths from covid-19.

The Sputnik V vaccine, developed by the Gamaleya National Research Center for Epidemiology and Microbiology, was the first coronavirus vaccine announced in the world and was registered in Russia on August 11, 2020. The drug has two components: the first is based on human adenovirus type 26, and the second is based on recombinant human adenovirus type 5. The drug is administered twice, with an interval of 21 days